Springworks Therapeutics, Inc.
SEC CIK 1773427 · [SWTX · last insider filing 2025-07-02
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Lynch Daniel | Director | filed 2019 - 2025 |
| Fuhrman Alan | Director | filed 2019 - 2025 |
| Mackay Martin | Director | filed 2024 - 2025 |
| Lewis-Hall Freda C | Director | filed 2019 - 2025 |
| Alban Carlos | Director | filed 2022 - 2025 |
| Islam Saqib | Director · Chief Executive Officer | filed 2019 - 2025 |
| Hambleton Julie | Director | filed 2020 - 2025 |
| Schwartz Jeffrey Lawrence | Director | filed 2019 - 2023 |
| Squinto Stephen P | Director | filed 2019 - 2022 |
| Patrick Deval L | Director | filed 2019 - 2019 |
| Gordon Carl L | Director | filed 2019 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Perier Francis I Jr | Chief Financial Officer | filed 2019 - 2025 |
| Weinstein Herschel S | General Counsel and Secretary | filed 2020 - 2025 |
| Nofi Michael | Chief Accounting Officer | filed 2019 - 2025 |
| Edris Badreddin | Chief Operating Officer | filed 2019 - 2025 |
| Pichl Daniel | Chief People Officer | filed 2020 - 2025 |
| Ashar Bhavesh | Chief Commercial Officer | filed 2021 - 2025 |
| Cassidy James | Chief Medical Officer | filed 2022 - 2025 |
| Lin Tai-An | Chief Scientific Officer | filed 2023 - 2025 |
| Smith L. Mary | See Remarks | filed 2019 - 2024 |
| Burgess Michael F. | Head of Research & Development | filed 2021 - 2022 |
| Renstrup Jens | Chief Medical Officer | filed 2019 - 2021 |
| Greco Michael V. | General Counsel & Secretary | filed 2019 - 2019 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.